Filing Flows › Harmony Biosciences Holdings (HRMY) › R&D spending
Harmony Biosciences Holdings (HRMY) R&D spending by quarter
Harmony Biosciences Holdings' R&D spending was $71.7M in Q3 2026 (third quarter 2026), +54% from Q2 2026. Over the last 7 quarters it ranged from $34.5M (Q1 2025) to $71.7M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $71.7M | +54% | +30% |
| Q2 2026 | $46.6M | -33% | -7% |
| Q1 2026 | $69.4M | +39% | +101% |
| Q4 2025 | $49.9M | -9% | — |
| Q3 2025 | $55.0M | +10% | — |
| Q2 2025 | $50.2M | +45% | — |
| Q1 2025 | $34.5M | — | — |
Q3 2026 at a glance
Harmony Biosciences Holdings, Q3 2026: revenue $269M (+12% year over year), operating margin 20.2%, net earnings $48.2M, operating cash flow $76.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Harmony Biosciences Holdings' R&D spending?
Harmony Biosciences Holdings' R&D spending was $71.7M in Q3 2026 (third quarter 2026), +54% from Q2 2026.
How has Harmony Biosciences Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $34.5M (Q1 2025) to $71.7M (Q3 2026).
Q3 2026 results → · How Harmony Biosciences Holdings makes money →